|Articles|February 15, 2008

February 2008
Volume 14
Issue 2

Newcomer (Am J Manag Care. 2007;13[suppl 7]:S170-S177)

Download PDF: Newcomer (Am J Manag Care. 2007;13[suppl 7]:S170-S177)

Articles in this issue

over 18 years ago

Article

Clancy et al (Am J Manag Care. 2008;14:39-44)

over 18 years ago

Article

Cost-effectiveness of Telephonic Disease Management in Heart Failure

over 18 years ago

Article

Long-term Cost Effects of Collaborative Care for Late-life Depression

over 18 years ago

Article

Practice Systems Are Associated With High-quality Care for Diabetes

over 18 years ago

Article

Oral Antidiabetic Medication Adherence and Glycemic Control in Managed Care

over 18 years ago

Article

Management of Chronic Noncancer Pain by VA Primary Care Providers: When Is Pain Control a Priority?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

The Timing and Characteristics of Supplemental Indications for Medicines

ByYingying Zhu, PhD,Claire H. Brennan, BA,Haijun Tian, PhD,Josephine N. Tran, PharmD, MS,Peter J. Neumann, ScD,James D. Chambers, PhD,Pei-Jung Lin, PhD,Meng Li, PhD

July 6th 2026

Newcomer (Am J Manag Care. 2007;13[suppl 7]:S170-S177)

Articles in this issue

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

The Timing and Characteristics of Supplemental Indications for Medicines

Trending on AJMC

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The Future of Myeloma Treatment: Ajai Chari, MD

COVID-19 Medicare Spending Falls After Acute Infection

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Newcomer (Am J Manag Care. 2007;13[suppl 7]:S170-S177)

Articles in this issue

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

The Timing and Characteristics of Supplemental Indications for Medicines

Trending on AJMC

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The Future of Myeloma Treatment: Ajai Chari, MD

COVID-19 Medicare Spending Falls After Acute Infection